Grifols : culminates a year of growth and approves the distribution of a record EUR 265 million in dividends

• Shareholders endorse the company's management and approve all items on the agenda
• Grifols' economic performance has centered on profitability and growth diversification, and its increase in shareholder retribution (21.5%) is in line with 2017 results
• The company's management has led to sales increases of its main divisions in all regions where it operates, achieving total revenues of more than EUR 4,300 million (6.6%) and EUR 663 million (21.5%) in net profit
• Grifols continues to place innovation and talent development as top priorities, allocating more than EUR 580 million to capital expenditures and innovation and expanding its staff by 23% to 18,300 employees
• The company optimized its financial structure, leading to an improved average cost of debt and longer maturities following a debt refinancing process
• Grifols co-CEOs have presented the 2017 Corporate Responsibility Report

Barcelona, May 25, 2018.- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global company that enhances the health and well-being of patients through the development of life-saving plasma-derived medicines, clinical diagnostics and pharmaceutical specialties for hospital use, and a forerunner in the research and development of therapeutic alternatives that drive scientific and social progress, held its Annual General Shareholders' Meeting on second call.

The meeting convened 536 shareholders who own 340,396,121 class A shares and represent 79.9% of share capital with voting rights. The votes delegated to the Board represented 75.0% of share capital, confirming shareholders' support of the Group's management and business plan.

Grifols' shareholders unanimously endorse the first year of Raimon Grífols Roura and Víctor Grífols Deu at the helm of the group's management

Grifols grew by 6.6% in 2017 to over EUR 4,300 million in total revenues, with a 21.5% increase in net profit to more than EUR 663 million. The increase in shareholder retribution (21.5%) is in line with 2017 results.

Grifols fulfilled its strategic objectives that guide the company's overall direction and continued to consolidate its plans to guarantee long-term sustainable growth.

In 2017, Grifols' financial performance focused on boosting profitability and growth diversification, which translated into increases in sales of its main divisions in all regions where it operates; promoting capital expenditure and innovation by allocating more than EUR 580 million in 2017; integrating the share of the NAT donor-screening technology unit acquired in early 2017 as a means to reinforce its leadership position in transfusional medicine; generating greater net cash flows, achieving a 43% increase to EUR 1,039 million; and optimizing its financial structure through a debt refinancing process that improved the average cost of debt and extended maturities.

In addition to ensuring a path of sustainable growth, the company continues to place innovation and talent development as top priorities.

Grifols allocated more than EUR 311 million in R+D+i in 2017 and more than EUR 1,300 million since 2013. The company's R+D+i strategy is built on a sustainable, long-term and integrated, focus that includes the development of in-house initiatives, as well as external projects through investee companies whose research complements Grifols' core activities.

Grifols' commitment to creating high-quality employment and offering ongoing training and professional development in 2017 led to its recognition as one of the 500 best global employers¹. The company's employee base grew by 23% to 18,300 employees; of which 58% are under 40 and 57% are women.

In Spain, the number of employees continued its upward trend, closing the year with a 6.3% increase compared to 2016 and a total of 3,645 jobs at the end of 2017. Of note is Grifols' expanding talent pool in the United States, where it has more than 3,100 employees. In ROW (rest of the world), the number of employees increased by 10%. More than 5,700 people have joined Grifols over the last five years.

Shareholder retribution increases by 21.5% in 2017 to EUR 0.38 per share

Grifols' shareholders approved the distribution of EUR 265.1 million in dividends (EUR 0.38 gross per share) in 2017, a company record that represents a 21.5% increase over 2016 and reflects the company's firm commitment to generate value for its shareholders. This total includes the preferred dividend of EUR 0.01 gross associated with each class B share.

The dividend will be paid out in two payments: an interim dividend paid in December 2017 of EUR 0.18 gross per share and a second payment of EUR 0.20 gross per share that will be distributed² from June 5, 2018 onwards.

The company maintains its pay-out of 40% of the group's consolidated net profits.

Corporate Governance

The shareholders endorsed the appointments of Mrs. Belén Villalonga Morenés and Mrs. Marla E. Salmon as independent directors, approved by the Board of Directors on April 27, 2018.

Grifols promotes a policy of gender balance and industry experience on its board of directors and committees. At present, women comprise more than 30% of Grifols' board members, surpassing the 2020 objective established by the CNMV Good Governance Code for publicly traded companies. In recent years the group has also bolstered the number of independent directors, which currently account for 54% of total members.

Beyond legal requirement and in compliance with best practices in corporate governance, Grifols' Board of Directors has a Lead Independent Director responsible for organizing common positions among independent directors to uphold and reinforce independence between the control and the management of the company.

Corporate Responsibility Report

Also presented at the General Shareholders' Meeting was the 2017 Corporate Responsibility Report, approved by the Board of Directors on April 27, 2018 as part of the company's longstanding commitment to transparency.

The report aims to offer Grifols' stakeholders a true and comprehensive overview of its social, environmental and economic performance in 2017, within the framework of the commitments assumed in its Corporate Social Responsibility Policy.

The Corporate Responsibility Report was prepared in accordance with the information requirements and guidelines of the Global Reporting Initiative (GRI) and verified by an external independent firm.

Approval of agenda items

Key agenda items ratified by the shareholders include:

• Approval of the individual and consolidated annual accounts
• Appointment and re-election of auditors
• Approval of the Annual Directors' Remuneration report, consultative vote

¹According to the annual ranking published by Forbes and Statista.
²Paid through Iberclear and its participating entities, with BBVA acting as the payment agent.